PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8424205

What is normal?

J H Koeslag
View original source ↗Export metadata ↓

Abstract

The distinction between normality and abnormality forms the basis of medical practice. However, these words appear to have no more precise meanings in medicine than they do in conversational English. At least five contradictory definitions are described in the literature, and are in simultaneous use in everyday practice. The apparently arbitrary manner in which these definitions are chosen to evaluate different phenomena effectively means that medicine operates without a definition: certain phenomena are normal (by decree, as it were), and others are not. Actions based on such an arbitrary system are, of necessity, haphazard. The adoption of a precise, rigorously acultural definition of normality would unquestionably admit medicine to full membership of the family of objective sciences.

Explore related subjects

DiagnosisHealthPhilosophy, MedicalSemanticsTerminology as TopicJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J H Koeslag. 1993. What is normal?. https://pubmed.ncbi.nlm.nih.gov/8424205/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

[Achievements and Expectations of the Rare Disease Diagnostic Support Program in the Republic of Korea].

OBJECTIVES: The Rare Disease Diagnostic Support Program in the Republic of Korea aims to improve early diagnosis and diagnostic yield for patients with rare diseases, particularly for those residing in non-metropolitan areas, by providing whole genome sequencing (WGS) services through regional medical institutions. This study evaluated the performance of the program, focusing on its clinical utility, including early diagnosis and treatment linkage, and its policy impact related to patient benefits. METHODS: From August 2024, WGS was performed on 410 patients with suspected rare diseases at 23 institutions outside the metropolitan area. A one-stop diagnostic pathway was established to perform sample collection, test referral, report delivery, and genetic counseling within a single clinical flow based on the patient’s location of residence. Sequencing was performed by external laboratories. RESULTS: Among the 410 patients, pathogenic variants were identified in 129 (31.5%), with a turnaround time of 28 days. Of those diagnosed, 78.2% received treatment benefits via national programs such as co-payment exemption and medical expense support programs. Approximately 30% of the patients were eligible for therapeutic intervention, particularly medication or dietary therapy. Family genetic testing of three members identified potential carriers or high-risk groups in 28 households (65.1%). Consent for secondary findings was 99.0%, with clinically significant variants found in 3.9% of cases. CONCLUSIONS: The program demonstrated clinical value by improving diagnostic accessibility, reducing regional disparities, facilitating timely treatment, and supporting preventive care through family risk identification. These findings support the need for sustainable expansion of genome-based diagnostic services in the national health policy.

Diagnosis↗